A 62-year-old man is evaluated in the ER for sudden onset of swelling of the right calf with pain for past 2 days. The patient noticed the swelling after he woke up from sleep and had pain while walking. He cannot recollect any history of trauma, denies any recent travel, and has never had a blood clot in the past His medical history is remarkable for hypertension, adequately controlled with lisinopril, and stage-III squamous cell carcinoma of the lung for which he recently completed six cycles of chemotherapy. On physical examination, there is tender swelling of the right calf without erythema. His D-dimer is 640 ng/mL. Venous Doppler of the right leg reveals occlusive thrombi in the deep veins. A plan is made to initiate anticoagulation and to extend the treatment for 6 months.What will be the drug of choice for anticoagulation for this patient?
A 62-year-old man is evaluated in the ER for sudden onset of swelling of the right calf with pain for past 2 days. The patient noticed the swelling after he woke up from sleep and had pain while walking. He cannot recollect any history of trauma, denies any recent travel, and has never had a blood clot in the past His medical history is remarkable for hypertension, adequately controlled with lisinopril, and stage-III squamous cell carcinoma of the lung for which he recently completed six cycles of chemotherapy. On physical examination, there is tender swelling of the right calf without erythema. His D-dimer is 640 ng/mL. Venous Doppler of the right leg reveals occlusive thrombi in the deep veins. A plan is made to initiate anticoagulation and to extend the treatment for 6 months.What will be the drug of choice for anticoagulation for this patient?
💡 Explanation
## **Core Concept**
The patient presents with symptoms and diagnostic findings consistent with **deep vein thrombosis (DVT)**, which is a type of venous thromboembolism (VTE). The management of DVT involves anticoagulation to prevent clot progression, reduce the risk of pulmonary embolism, and minimize the risk of post-thrombotic syndrome. The choice of anticoagulant depends on several factors, including the patient's risk factors for bleeding, renal function, and the presence of cancer.
## **Why the Correct Answer is Right**
The correct answer, **Low Molecular Weight Heparin (LMWH)**, is the drug of choice for anticoagulation in this patient for several reasons:
- The patient has **cancer**, which is a hypercoagulable state and increases the risk of recurrent VTE. LMWH has been shown to be more effective than oral anticoagulants in preventing recurrent VTE in patients with cancer.
- LMWH does not require regular monitoring of coagulation parameters like **International Normalized Ratio (INR)** and is less likely to interact with other medications, making it a practical choice for patients with cancer who may have fluctuating renal function or be on multiple medications.
- The patient has **recently completed chemotherapy**, which might affect oral absorption and metabolism of oral anticoagulants.
## **Why Each Wrong Option is Incorrect**
- **Option A (Aspirin):** Aspirin is not sufficient as a standalone treatment for DVT due to its antiplatelet effects and does not adequately address the coagulation cascade involved in clot formation in DVT.
- **Option B (Warfarin):** Warfarin, an oral vitamin K antagonist, is not the preferred initial treatment in a patient with cancer due to its increased risk of bleeding, interactions with chemotherapy agents, and the need for regular INR monitoring.
- **Option D (Fondaparinux):** Fondaparinux is a synthetic pentasaccharide anticoagulant that is effective for VTE prevention and treatment but is not typically the first choice for long-term treatment of DVT, especially in a cancer patient, compared to LMWH.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that patients with cancer and VTE are generally recommended to receive **LMWH for at least 6 months** as the initial anticoagulant therapy due to its efficacy in reducing the risk of recurrent VTE compared to oral anticoagulants.